Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

MDWD

Phase 3

EscharEx

VLU (Venous Leg Ulcers)

Mid-2026

Ph3 VALUE Study. Collab w/ MIMEDX, Mölnlycke & 3M Health Care. 2/12/25- Initiated Ph3 trial. 3/19/25- Interim analysis in mid-2026.

Data readout

ANRO

Phase 2b

ALTO-300

Major Depressive Disorder

mid-2026

2/12/25- Reported favorable outcome from the planned interim analysis. Topline results in mid-2026.

Data readout

ARGX

Phase 3

Empasiprubart

Multifocal motorneuropathy (MMN)

H2 2026

EMPASSION trial. 6/25/24 Top-line results from 1st cohort at PNS '24. Reports data from 2nd cohort later in 2024. 10/15/24 Presentation at AANEM '24. Initiate Ph3 in Q4 '24. 2/27/25- Topline data in H2 2026.

Data readout

AXSM

Phase 3

Solriamfetol

Binge eating disorder

2026

ENGAGE trial. 4/1/24- Ph3 initiated. 2/18/25- Topline data in 2026.

Data readout

IPSEY

Phase 3

Tazemetostat + rituximab + lenalidomide

R/R FL (Relapsed or Refractory Follicular Lymphoma)

2026

SYMPHONY-1 Ph3 trial: First patient dosed on 3/15/22. Updated Phase 1b data presented at ASCO 06/3-7/2022. 8/21/23- Initial data in 2026.

Data readout

RVMD

Phase 3

Daraxonrasib (RMC-6236)

2L metastatic pancreatic ductal adenocarcinoma

2026

RASolute 302 Ph3 trial. 10/22/24- First patient dosed. 2/26/25- Complete enrollment in 2025; data in 2026.

Data readout

RGNX

Phase 2

ABBV-RGX-314 (Subretinal Delivery)

Wet AMD (Wet age-related macular degeneration) (ATMOSPHERE and ASCENT)

2026

ATMOSPHERE®/ASCENT/FET studies. In collab w/ AbbVie. Global regulatory submissions w/ FDA and EMA in H1 2026. 10/21/24 Present positive Ph2 data at AAO 2024. 1/13/25- Pivotal data expected in 2026.

Data readout

IVA

Phase 3

Lanifibranor (Pan-PPAR)

NASH (Nonalcoholic steatohepatitis)

H2 2026

NATiV3 Trial. 3/7/24- Voluntary pause lifted, resuming patient screening. 7/5/24 Last patient first visit in H2 2024. 10/14/24 Complete enrollment in H1 2025 & topline data at the beginning of H2 2026.

Data readout

SLGL

Phase 3

SGT-610 (Patidegib)

Gorlin Syndrome

H2 2026

Received FDA ODD. 11/30/23- Screened first patient. 11/15/24- Topline data in H2 2026.

Data readout

BMY

Phase 3

KarXT (M1/M4 muscarinic agonist)

Alzheimer's-related Psychosis

2026

ADEPT trial. 11/2/23- Initiated ADEPT-2 and ADEPT-3 trials in Q3 '23. Topline data from ADEPT-1 and ADEPT-2 in 2026. 03/18/24- Company acquired by BMY.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20